TNFα antagonist continuation rates in 442 patients with inflammatory joint disease

Joint Bone Spine

Volumn 74, Issue 2, 2007, Pages 148-154

  Brocq, Olivier ^a   Roux, Christian Hubert ^a   Albert, Christine ^a   Breuil, Véronique ^a   Aknouche, Nicolas ^a   Ruitord, Sandra ^a   Mousnier, Aline ^a   Euller Ziegler, Liana ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Chronic inflammatory joint disease; Rheumatic disease; TNF antagonist; Treatment continuation rate

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; CLINICAL PRACTICE; COMORBIDITY; DRUG ANTAGONISM; DRUG COMBINATION; FRANCE; INFECTION; LYMPHOMA; MIDDLE AGED; PATIENT COMPLIANCE; STATISTICS;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; INFECTION; LYMPHOMA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247161469     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.06.011     Document Type: Article

References (40)

1. Sany J. Nouvelles biothérapies dans le traitement de la polyarthrite rhumatoïde. Rev Rhum 66 (1999) 625-637
2. Hochberg M.C., Tracy J.K., Hawkins-Holt M., and Flores R.H. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2 Suppl (2003) 30-33
3. Maini R., St Clair E.W., Breedveld F.C., Furst D., Kalden Y., Weisman M., et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomittant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 354 (1999) 1932-1939
4. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleishmann R.M., Bulpitt K.Y., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 (1999) 478-481
5. Weisman M.H., Moreland L.W., Furst D.E., Weinblatt M.E., Keystone E.C., Paulus H.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a full human anti-tumor necrosis factor-alpha monoclonal antibody, in adults rheumatoid arthritis receiving concomittant methotrexate: a pilot study. Clin Ther 25 (2003) 1700-1721
6. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.Y., Fleishmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
7. Genta M.S., Kardes H., and Gabay C. Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF alpha in the community. Joint Bone Spine 73 (2006) 51-56
8. Richard-Miceli C., Maillefert J.F., and Dougados M. Pertinence clinique de la réduction de la progression radiographique sous anti-TNF, au cours de la polyarthrite rhumatoïde. Rev Rhum (Ed Fr) 1 Suppl (2001) 3-9
9. Sany J. Quand commencer et comment surveiller un traitement par un agent anti-TNF alpha au cours de la polyarthrite rhumatoïde?. Rev Rhum (Ed Fr) 1 Suppl (2001) 11-16
10. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
11. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50 (2004) 2264-2272
12. Cohen G., Courvoisier N., Cohen J.D., Zaltni S., Sany J., and Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 23 (2005) 795-800
13. Brocq O., Plubel Y., Breuil V., Grisot C., Flory P., Mousnier A., et al. Etanercept-infliximab switch in rheumatoid arthritis: 14 out of 131 patients treated with anti-TNF alpha. Presse Med 31 (2002) 1836-1839
14. Van Vollenhoven R., Harju A., Brannemark S., and Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 62 (2003) 1195-1198
15. Arnett F.C., Edworthy S.M., and Block D.A. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
16. Van Der Linden S., Valkenburg H.A., and Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 (1984) 361-368
17. Moll J.M., and Wright V. Psoriatic arthritis. Semin Arthritis Rheum 3 (1973) 55-78
18. Van Gestel A.M., Prevoo M.L., Van't Hof M.A., Van Rijswijk M.H., Van De Putte L.B., and Van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for Rheumatoid Arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39 (1996) 34-40
19. Anderson J.J., Baron G., Van Der Heijde D., Felson D.T., and Dougados M. Ankylosing spondylitis assessment group preliminary definition of short term improvement in ankylosing spondylitis. Arthritis Rheum 44 (2001) 1876-1886
20. Clegg D.O., Reda D.J., Mejias E., Cannon G.W., Weisman M.H., Taylor T., et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39 (1996) 2013-2020
21. Chung P., Mallon C., Spady B., Russell A.S., and Maksymowych W.P. Survival analysis of treatment with leflunomide, combination leflunomide/mehtotrexate, and infliximab for rheumatoid arthritis in routine clinical practice. Arthritis Rheum 48 Suppl (2003) S334 (abstract)
22. Flendrie M., Creemers M.C.W., Welsing P.M.J., Den Broeder A.A., and Van Riel P.L.C. Survival on three TNF blocking agents in rheumatoid arthritis. Arthritis Rheum 48 Suppl (2003) S334 (abstract)
23. Ducoulombier V., Solau E., Coquerelle P., Houvenagel E., Siame J.L., Desprez X., et al. Suivi à long terme (2 ans) de polyarthrites rhumatoide traitées par infliximab: l'expérience du réseau hospitalier nord pas de calais. Rev Rhum 71 (2004) 438 (abstract)
24. Wendling D., Materne G.E., Michel F., Lohse A., Lehuede G., Toussitot E., et al. Infliximab continuation rate in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 72 (2005) 628-631
25. Ethgen M., Sordet C., Demesmay K., Cohen-Solal J., Javier R.M., Koffel J.C., et al. Analyse rétrospective de la maintenance thérapeutique de l'infliximab dans une cohorte de polyarthrites rhumatoïdes. Rev Rhum 71 (2004) 10-11
26. Zink A., Listing J., Kary S., Ramlau P., Stoyanova-Scholz M., Babinsky K., et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64 (2005) 1274-1279
27. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
28. Weinblatt M.E., Keystone E.C., Furst D.E., Kavanaugh A.F., Chartash E.K., and Segurado O.G. Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann Rheum Dis 65 (2006) 753-759
29. Dumoulin C., Richez C., Mehsen N., Bentaberry F., Monnier A., Dehais J., et al. Maintenance rates of antiTNF agents in rheumatoid arthritis patients in daily practice. Arthritis Rheum 9 Suppl (2004) S398
30. Duclos M., Gossec L., Ruyssen A., Salliot K., Luc M., Guignard S., et al. Retention rates of TNF blockers in daily practice: drug comparisons and predisposing factors in 770 patients. Arthritis Rheum 9 suppl (2005) S565
31. Braun J., Brandt J., Listing J., Zink A., Alten R., Burmester G., et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64 (2005) 229-234
32. Nikas S.N., Alamanos Y., Voulgari P.V., Pliacou X.I., Papadopoulos C.G., and Drosos A.A. Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 64 (2005) 940-942
33. Davis J.C., Van der Hejde D.M., Braun J., Dougados M., Cush J., Clegg D., et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64 (2005) 1557-1562
34. Heiberg M.S., Nordvag B.Y., Mikkelsen K., Rodevand E., Kaufmann C., Mowinckel P., et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six month, longitudinal, observational, multicenter study. Arthritis Rheum 52 (2005) 2506-2512
35. Carmona L., Gomez Reino J.J., and BIOBASADER. Study Group. Do biologics work better for spondylarthritis than for rheumatoid arthritis? The BIOBASADER Experience. Arthritis Rheum 9 Suppl (2005) S280
36. Antoni C., Krugger G., De Vlam K., Birbara C., Beutler A., Guzzo C., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 t. Ann Rheum Dis 64 (2005) 1150-1157
37. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., and Choy E.H. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
38. Tubach F., Salmon-Ceron D., Ravaud P., Mariette X., and For the RATIO Study Group. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNF alpha therapy. Joint Bone Spine 72 (2005) 456-460
39. Askling J., Fored C.M., Baecklund E., Brandt L., Backlin C., Ekbom A., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64 (2005) 1414-1420
40. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius L., et al. Risks of solid cancers in patient with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis 64 (2005) 1421-1426